Loading...
Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction
AnalystLowTarget's Fair Value
US$26.00
20.3% undervalued intrinsic discount03 Sep
US$20.73
1Y
184.0%7D
-7.8%1Y
184.0%7D
-7.8%You can edit this narrative until Sep 3 10:14 PM. Then, changes will post as Updates.